Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Keywords: RECEPTOR ; ANGIOGENESIS ; CANCER ; EXPRESSION ; GROWTH ; GROWTH-FACTOR ; proliferation ; SURVIVAL ; Germany ; LUNG ; lung cancer ; LUNG-CANCER ; RISK ; PATIENT ; PERFORMANCE ; TRIAL ; metastases ; chemotherapy ; PROGNOSTIC-FACTORS ; CARCINOMAS ; PROGNOSTIC FACTORS ; PROGNOSTIC VALUE ; PROGNOSTIC FACTOR ; VEGF ; non-small cell lung cancer ; SERUM ; MATRIX ; overall survival ; PROGNOSTIC-FACTOR ; LEVEL ; PHASE ; PROFILES ; SERUM-LEVELS ; MATRIX-METALLOPROTEINASE-9 ; MMP-9 ; angiogenic factors ; COUNTS ; NSCLC ; PLATELET
    Abstract: Purpose: In the present study, we investigated the prognostic value of vascular endothelial growth factor (VEGF) and matrix metalloproteinase (MMP)-9 serum levels in patients with metastatic non-small cell lung cancer (NSCLC). Patients and methods: From September 1999 to June 2001, pretreatment serum levels of VEGF and MMP-9 were analysed in 194 patients of a randomized phase III trial with enzyme-linked immunoassays. Results: Patients with a VEGF serum level higher than the median serum level (10,995 pg/ml) had a significantly shorter overall survival than those with a lower serum level (P=0.04). The MMP-9 serum level did not correlate with survival. In a multivariate Cox regression analysis, only the pretreatment serum level of VEGF, the Karnofsky performance status, and the presence of bone metastases were identified as independent prognostic factors. Conclusions: The pretreatment VEGF serum level was identified as independent prognostic factor in this study and may help to assess individual risk and treatment profiles in patients with metastatic NSCLC. (c) 2005 Elsevier Ireland Ltd. All rights reserved
    Type of Publication: Journal article published
    PubMed ID: 15992959
    Signatur Availability
    BibTip Others were also interested in ...
  • 2
    Keywords: CANCER ; CELLS ; EXPRESSION ; SURVIVAL ; carcinoma ; CELL ; Germany ; LUNG ; lung cancer ; LUNG-CANCER ; SYSTEM ; SITE ; SITES ; SURGERY ; PATIENT ; MARKER ; tumour ; BINDING ; ASSOCIATION ; GLYCOPROTEIN ; PROGRESSION ; METASTASIS ; metastases ; PROGNOSTIC-FACTORS ; adenocarcinoma ; glycosylation ; LECTIN ; OLIGOSACCHARIDES ; ONCOLOGY ; methods ; adenocarcinoma of the lung ; PROMOTION ; BINDING-SITE ; lymph node metastases ; correlation ; metastatic potential ; LECTINS ; HUMAN-BREAST ; clinical study ; haematogenous metastases ; HELIX-POMATIA AGGLUTININ ; HPA ; HPA BINDING ; PHA-L ; UEA-I
    Abstract: Background: Several clinical studies indicate that primary tumour cells with high metastatic potential often show aberrant glycosylation as detected by lectin histochemistry. However, it is unclear whether aberrant glycosylation is still present in metastatic deposits. The aim of the present investigation was thus to analyse a possible association between the presence of lectin binding sites of pulmonary adenocarcinoma cells and their lymph node and haematogenous metastatic cells. Methods: For this purpose, the expression of HPA, PHA-L and UEA-I was assessed in primary tumours, lymph node metastases and haematogenous metastases of 96 patients with metastatic adenocarcinomas of the lung that underwent surgery between 1999 and 2002. Besides, lectin-binding data and other known prognostic factors were correlated with survival. Results: We found a significant positive correlation between the binding of the lectins HPA (p = 0.002), PHA-L (p 〈 0.00001) and UEA-I (p 〈 0.00001) to the cells of the primary tumour and to their lymph node metastases. There was a positive correlation between the binding of HPA to the cells of the primary tumour and the haematogenous metastases as well. Patients with tumours which did not show HPA binding sites had a median overall survival of 27.9 months (95%-Cl 7.7-infinity months). Patients with a HPA binding tumour had a median overall survival of 20.9 months (95%-CI 18.5-28.7 months). Conclusion: This is the first investigation to demonstrate a positive correlation between the binding of the lectins HPA, PHA-L and UEA-I to the cells of the primary tumour and to their Lymph node metastases. Expression of HPA binding sites is also preserved in the haematogenous metastases. In summary, our results support the hypothesis that altered glycosylation of the membrane-bound glycoproteins of the tumour cells is associated with, but not sufficient for promotion of lymphogenic and haematogenous metastasis. (c) 2007 Elsevier Ireland Ltd. All rights reserved
    Type of Publication: Journal article published
    PubMed ID: 17306412
    Signatur Availability
    BibTip Others were also interested in ...
  • 3
    Keywords: PEPTIDE ; RECEPTOR ; ANGIOGENESIS ; CANCER ; EXPRESSION ; IN-VITRO ; SURVIVAL ; carcinoma ; ENDOTHELIAL GROWTH-FACTOR ; Germany ; IN-VIVO ; LUNG ; THERAPY ; VITRO ; lung cancer ; LUNG-CANCER ; GENE ; GENES ; PROTEIN ; PATIENT ; FAMILY ; CONTRAST ; antibodies ; antibody ; IN-SITU ; immunohistochemistry ; PROGNOSTIC VALUE ; RECEPTORS ; PROGNOSTIC FACTOR ; SERUM ; ELISA ; cancer therapy ; SERUM-LEVELS ; advanced NSCLC ; FACTOR EXPRESSION ; ROBO 4 ; SLIT2
    Abstract: Background: Magic Roundabout (MR; ROBO 4) is a recently discovered gene which encodes a protein that derived its name form the structural homology with the roundabout family of genes. Genes of the roundabout family comprise neuronal-specific cell surface receptors that are involved in axon guidance. MR in contrast showed endothelial specificity in vitro and in vivo using immunohistochemistry and in situ hybridisation. The putative rote of MR as an endothelial analogue of Roundabout in angiogenesis makes it an attractive target for anti-angiogenic cancer therapy. Patients and methods: Using specific antibodies against MR peptide, we screened pretreatment sera from 193 patients with advanced non-small cell lung cancer (NSCLC) for MR-protein levels. Results: Patients with serum Levels of MR-protein tower than median (E-450nm = 0.652) had a median survival of 41.0 weeks whereas those with a higher serum level had a considerably shorter median survival of 32.4 weeks (P = 0.05). The pretreatment serum level of MR-protein achieved no significance in a univariate Cox regression analysis. Conclusions: This is the first study to present clinical data that link MR expression with outcome in patients with NSCLC, whether the correlation of pretreatment serum levels of MR and survival can be attributed to MR dependent angiogenesis remains to be investigated. (c) 2005 Elsevier Ireland Ltd. ALL rights reserved
    Type of Publication: Journal article published
    PubMed ID: 15949592
    Signatur Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...